The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer

OBJECTIVE: Although the current European Association of Urology(EAU) guideline recommends that patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) should accept intravesical chemotherapy or Calmette-Guerin (BCG) for no more than one year after transurethral resection of bladde...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jian-Xin, Huang, Wen-Ting, Zhang, Qing-Yun, Deng, Cheng-En, Wei, Jue-ling, Xie, Yuan-Liang, Lin, Rui, Feng, Guan-Zheng, Yang, Guang-Lin, Long, Jun, Lu, Hao-Yuan, Mo, Zeng-nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591423/
https://www.ncbi.nlm.nih.gov/pubmed/37872516
http://dx.doi.org/10.1186/s12885-023-11523-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591423/
https://www.ncbi.nlm.nih.gov/pubmed/37872516
http://dx.doi.org/10.1186/s12885-023-11523-9

Ejemplares similares